GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Neuland Laboratories Ltd

Neuland Laboratories Recommends Rs. 3.4/share Final Dividend

DIVIDEND ▲ Positive Development LOW RISK
📅 Filed on BSE: 12 May 2026, 06:02 PM IST  ·  BSE ID: 85923ecb-627a-4451-a8f7-627525562883
View Original BSE Filing (PDF)
💡
In Simple Terms
The company recommended a Rs. 3.4 per share dividend and plans a Rs. 143.4 crore factory expansion.
🤖 AI Summary
  • Board recommended a final dividend of Rs. 3.4/- per equity share (340%) for FY2025-26.
  • The record date for determining dividend eligible shareholders is July 24, 2026.
  • Approved capacity expansion of 120.5 KL at Unit 1, requiring an investment of Rs. 143.4 crore.
  • Dr. M. Aturi Fuitor appointed as an Additional Non-Executive Non-Independent Director, effective May 12, 2026.
  • The 42nd Annual General Meeting of shareholders is scheduled for Tuesday, August 4, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Final Dividend per Equity Share
Rs. 3.4/-
Proposed Additional Capacity at Unit 1
120.5 KL
Investment for Capacity Expansion
Rs. 143.4 crore
🏢 How This Affects the Company
📈
Business Impact
The approved capacity expansion of 120.5 KL at Unit 1 aims to maintain and cater to the growing demand from customers, potentially supporting future revenue growth.
💰
Financial Impact
The Rs. 143.4 crore investment for capacity expansion will be financed through internal accruals and borrowings, impacting the company's cash flow and potentially increasing its debt profile. The dividend payout will reduce retained earnings.
⚙️
Operational Impact
The addition of 120.5 KL capacity at Unit 1 will enhance production capabilities, requiring 12 to 18 months for completion.
👥 What This Means For Shareholders
✅
Action Required
Shareholders who wish to receive the final dividend must ensure their shares are held in their demat account by the record date of July 24, 2026.
👤
Who Is Affected
All shareholders on record as of July 24, 2026, will be eligible to receive the final dividend of Rs. 3.4/- per equity share.
🔍
Management Signal
The dividend recommendation signals management's intent to distribute profits to shareholders, while the capacity expansion indicates a focus on future growth and meeting market demand.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Dividend payment date — monitor confirmation after 42nd AGM approval.
Progress on capacity expansion — check for updates on project timeline and costs.
Q1 FY27 results — assess financing details and impact of expansion on financials.
LOW RISK The filing primarily details a dividend recommendation and a strategic capacity expansion plan.
💡 Investor Takeaway
Neuland Laboratories recommended a final dividend of Rs. 3.4/- per equity share (340%) for FY2025-26, with July 24, 2026, as the record date. Additionally, the company approved a capacity expansion of 120.5 KL at Unit 1, involving an investment of Rs. 143.4 crore.
⚖️ Strengths & Concerns

✅ Positives

  • Recommendation of a final dividend of Rs. 3.4/- per equity share reflects a commitment to shareholder returns for FY2025-26.
  • Approved capacity expansion of 120.5 KL at Unit 1, with a Rs. 143.4 crore investment, supports catering to growing customer demand.
📅 Company Track Record
Neuland Laboratories has consistently recommended final dividends, with past filings on May 12, 2026, also mentioning a Rs. 3.4 final dividend for FY2025-26 and previously setting July 24, 2026, as the record date. This filing confirms the final dividend amount and provides details on the capacity expansion.

Based on publicly available historical data. For context only.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.